D.E. Shaw & Co
FRTX

D.E. Shaw & Co’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

D.E. Shaw & Co’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-158
Closed -$470K – 3912
2015
Q1 		$470K Sell
158
-1
-0.6% -$3.2K ﹤0.01% 3084
2014
Q4 		$526K Sell
159
-24
-13% -$85K ﹤0.01% 3287
2014
Q3 		$646K Sell
183
-139
-43% -$540K ﹤0.01% 3150
2014
Q2 		$1.24M Sell
322
-10
-3% -$37.6K ﹤0.01% 2739
2014
Q1 		$1.35M Buy
332
+318
+2,271% +$1.42M ﹤0.01% 2774
2013
Q4 		$53K Buy
+14
New +$53K ﹤0.01% 4393
2013
Q3 		– Sell
-4
Closed -$42K – 4504
2013
Q2 		$42K Buy
+4
New +$44.3K ﹤0.01% 3925

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co's FRTX Position: Q2 2015 in Review

D.E. Shaw & Co sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2015, closing a stake of 158 shares — an estimated $470K sold.

D.E. Shaw & Co first reported a position in FRTX in Q2 2013 and held it in 7 quarters. The position peaked at $1.35M in Q1 2014. 58 funds tracked by Wall St. Rank hold FRTX as of Q2 2015.

  • D.E. Shaw & Co reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • D.E. Shaw & Co sold 158 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $470K.
  • D.E. Shaw & Co first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 7 quarters.
  • D.E. Shaw & Co's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.35M in Q1 2014.
  • 58 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2015.

Based on D.E. Shaw & Co's 13F filing for Q2 2015, filed 14 Aug 2015.